Skip to content

Endoscopic Retrograde Cholangiopancreatography

Endoscopic Retrograde Cholangiopancreatography Patient Registry

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07490132
Enrollment
100
Registered
2026-03-24
Start date
2026-02-01
Completion date
2028-02-01
Last updated
2026-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastro-Intestinal Disorder

Brief summary

The risk of post-endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis(PEP) is influenced by patient and procedure-related factors. Strategies to decrease PEP(Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis) are of great importance.

Detailed description

The primary objective of this study is to provide a mechanism to store the following information about patients undergoing ERCPs at Methodist Dallas Medical Center. This registry will be permissive of quality improvement and research studies.

Interventions

OTHERPatients undergoing ERCPs at Methodist Dallas Medical Center

The registry will include all patients who meet registry inclusion. Enrollment will terminate once 25 years of data are captured: January 1, 2000 through December 31, 2025.

Sponsors

Methodist Health System
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients \>15 years Included in MDI's Registry Underwent ERCP between January 1, 2000 through December 31, 2025

Exclusion criteria

Patients \<15 years Patients in which cannulation was via a surgical anastomosis Patients in which cannulation was not attempted due to gastric outlet obstruction, the main papilla not found, or the minor papilla was not found will be excluded.

Design outcomes

Primary

MeasureTime frameDescription
Underwent ERCP25 yearsPatients undergoing ERCPs at Methodist Dallas Medical Center.

Countries

United States

Contacts

CONTACTCrystee Cooper, DHEd
ClinicalResearch@mhd.com214-947-1280
CONTACTKavya Mankulangara
ClinicalResearch@mhd.com214-947-4604
PRINCIPAL_INVESTIGATORPrashant Kedia, MD

Methodist Health System

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026